Table 1.
Summary of combination treatments of chemotherapy and stromal targeting agents.
| Molecular target | Treatment combination | Cancer type | Clinical trial | Outcome | Reference |
|---|---|---|---|---|---|
| CSF1R | Pexidartinib (PLX3397) (αCSF-lR) + eribulin | Metastatic breast cancer | Phase 1/2 NCT01596751 | Ongoing | |
| Pexidartinib (PLX3397 αCSF-lR) + paclitaxel | Solid tumors | Phase 1 NCT01525602 | ORR: 4/23 (17%) CBR: 14/23 (61%) | Rugo et al., 2014 | |
| CSF1 | MCS110 (αCSFl) + carboplatin plus gemcitabine | Triple negative breast cancer | Phase 2 NCT02435680 | Ongoing | |
| CCL2 | CNTO888 (αCCL2) + DOXIL®/Caelyx® doxorubicin HC1 liposome injection CNTO888 + gemcitabine CNTO888 + paclitaxel and carboplatin CNTO888 + docetaxel | Solid tumors | Phase 1 NCT01204996 | Hematological complications in >93% | |
| CNTO888 + docetaxel | Metastatic resistant prostate cancer | Phase 2 NTC00992186 | 34% maintained stable disease | ||
| CD40 | Dacetuzumab + bortezomib | Relapsed or refractory multiple myeloma | Phase 1 NCT00664898 | Completed results not posted | |
| Dacetuzumab + R-ICE (rituximab, etoposide, carboplatin, ifosfamide) | Diffuse large B cell lymphoma | Phase IIb NCT00529503 | Terminated | ||
| Smo | LDE225 (αSmo) + temozolomide | Medulloblastoma | Phase 3 NCT01708174 | ORR: 18.8% | Kieran et al., 2013 |
| IGF | BI 836845 + enzalutamide | Castration-resistant Prostatic neoplasms | Phase 1 NCT02204072 | Ongoing | |
| BI 836845 + everolimus + exemestane | HR+/HER2- advanced breast cancer | Phase 1 NCT02123823 | Ongoing | ||
| MEDI-573 + aromatase inhibitor | HER-2 negative metastatic breast cancer | Phase 2 NCT01446159 | Ongoing |